睡茄提取物(Withania somnifera Extract) - 药物靶点：SLC8A3_在研适应症：肌萎缩侧索硬化，阿尔茨海默症_专利_临床

概要

基本信息

药物类型

中药

别名

Withania somnifera roots extract

靶点

SLC8A3

作用机制

SLC8A3 agonists(solute carrier family 8 member A3 agonists)

治疗领域

神经系统疾病内分泌与代谢疾病其他疾病

在研适应症

肌萎缩侧索硬化阿尔茨海默症

非在研适应症

广泛性焦虑障碍精神分裂症

原研机构-

在研机构

华中科技大学

WellSpring School of Allied Health

Sunnybrook Health Sciences Centre

非在研机构

University of California, Los Angeles

Natreon, Inc.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)临床前

特殊审评-

登录后查看时间轴

关联

4

项与睡茄提取物相关的临床试验

CTRI/2024/03/064007 / Completed临床3期IIT

Effects of Eight weeks Supplementation of Withania Somnifera on Biochemical and Physical Components Among Football Players - Nil

开始日期2024-03-24

申办/合作机构-

NCT05031351 / Recruiting临床2期IIT

Nuclear Factor Kappa Beta Inhibition in Patients With Amyotrophic Lateral Sclerosis: A Phase II Randomized Placebo Controlled Trial

This is a Phase II, single centre, randomized, parallel, double blind, placebo-controlled clinical trial to determine the safety of Withania somnifera in participants with Amyotrophic Lateral Sclerosis (ALS).

开始日期2021-10-19

申办/合作机构

Sunnybrook Health Sciences Centre

NCT03437668 / Terminated临床2/3期IIT

Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia

To determine whether a standardized extract of Withania somnifera will reduce psychopathology scores (PANSS total score) in persons with schizophrenia. A secondary aim is to determine whether WSE reduces measures of positive and negative symptoms (PANSS subscales) and stress scores on the Perceived Stress Scale (PSS).

开始日期2018-12-01

申办/合作机构

University of Maryland

[+1]

100 项与睡茄提取物相关的临床结果

登录后查看更多信息

100 项与睡茄提取物相关的转化医学

登录后查看更多信息

100 项与睡茄提取物相关的专利（医药）

登录后查看更多信息

6

项与睡茄提取物相关的文献（医药）

2024-11-01·Human Psychopharmacology: Clinical and Experimental

Safety and efficacy of Withania somnifera for anxiety and insomnia: Systematic review and meta‐analysis

Review

作者: Raza, Ghana ; Waseem, Areesha ; Fatima, Kaneez ; Muskan, Fariha ; Rashid, Ahmed Mustafa ; Shaikh, Yasmeen ; Khan, Umeed ; Shahid, Hiba ; Zaheer, Muhammad Kashan ; Malik, Javeria ; Jaffery, Syeda Fatima

AbstractObjectiveDespite the historical neurological use of Withania somnifera, limited evidence supports its efficacy for conditions like anxiety and insomnia. Given its known anti‐stress properties, this review evaluated its safety and efficacy for anxiety and insomnia.MethodsWe searched Medline, Cochrane Library, and Google Scholar until August 2023 for randomized controlled trials (RCTs) comparing W. somnifera to placebo in patients with anxiety and/or insomnia. Outcome measures included changes in anxiety levels via the Hamilton Anxiety Scale (HAM‐A), Sleep Onset Latency (SOL), Total Sleep Time (TST), Wake After Sleep Onset (WASO), Total Time in Bed (TIB), Sleep Efficiency (SE), and Pittsburgh Sleep Quality Index (PSQI) score. We utilized a random‐effect model for pooling Mean Differences (MD) with a 95% Confidence Interval (CI). Heterogeneity was assessed through sensitivity and subgroup analysis, and the quality of RCTs was evaluated using the Cochrane revised risk of bias tool.ResultsPooled results from five RCTs (n = 254) demonstrated that W. somnifera significantly reduced HAM‐A scores (MD = −5.96; [95% CI −10.34, −1.59]; P = 0.008; I2 = 98%), as well as sleep parameters such as SOL, TST, PSQI, and SE, but not WASO and TIB.ConclusionWhile W. somnifera extracts yielded promising results, further research with larger sample sizes is needed to confirm its effects on anxiety and insomnia.

2021-12-28·Cureus

Withania somnifera as an Adjunctive Treatment for Refractory Restless Legs Syndrome in Parkinson’s Disease: A Case Report

作者: Chaudhari, Kaustubh S ; Tiwari, Rakesh R ; Singh, Harish B ; Joshi, Swati V ; Chaudhari, Saurabh S

Non-motor symptoms of Parkinson's disease (PD), such as insomnia and restless legs syndrome (RLS), tend to worsen and become refractory as neurodegeneration progresses. We report the case of a 72-year-old female with a six-year history of PD and two-and-half-year history of insomnia and refractory RLS. We added a neuroprotective agent, Withania somnifera, to the existing treatment regimen for her insomnia. Besides the partial remission of her insomnia and motor symptoms of PD, there was a complete reversal of the RLS symptoms. Withania somnifera has been shown to improve PD symptoms by preventing oxidative damage of the nigrostriatal dopaminergic neurons and improving dopamine levels in the midbrain and corpus striatum. Our case provides the first-time evidence where Withania somnifera added for insomnia caused a complete remission of refractory RLS, possibly due to its anti-apoptotic and pro-dopaminergic actions. Withania somnifera could prove beneficial in cases where the disease advances but further addition of dopamine agonists for refractory RLS is not possible due to the risk of dopamine augmentation.

2019-06-01·Clinical Immunology3区 · 医学

Effect of Withania somnifer on CD38 expression on CD8+ T lymphocytes among patients of HIV infection

3区 · 医学

Article

作者: Tyagi, Sonu ; Das, Bimal Kumar ; Singh, Ravinder ; Maurya, Shesh Prakash

CD38 on CD8 + T cells is considered a reliable marker of HIV disease progression. Withania somnifer, a traditional ayurvedic medicine, has Th1 immunomodulatory properties. PBMCs from 38 HIV patients were exposed to Withania somnifer root extract at standardized concentration. An overall decline in the percentage of CD38 expressing CD8 + T lymphocytes was observed, though the statistical significance was varied with different categories of HIV patients. Withania somnifer could have promising impact on HIV disease and therefore warrants a further study on larger parameters.

100 项与睡茄提取物相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肌萎缩侧索硬化	临床2期	加拿大	Sunnybrook Health Sciences Centre	2021-10-19
广泛性焦虑障碍	临床2期	印度	Natreon, Inc.	2011-03-01
精神分裂症	临床1期	美国	University of California, Los Angeles	2018-12-01
阿尔茨海默症	临床前	中国	华中科技大学	2022-12-20
阿尔茨海默症	临床前	美国	WellSpring School of Allied Health	2022-12-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03437668 (CTgov)	临床2/3期	精神分裂症	47	WSE (Withania Somnifera Extract (WSE))	壓壓觸窪獵簾壓淵範衊(願窪餘積齋鹽構鹽糧蓋) = 遞廠積獵窪壓廠鏇衊積構選壓夢築繭醖壓繭製 (積膚網蓋範鹹願遞築簾, 膚範夢鬱淵鑰築繭憲網 ~ 膚鬱醖鹹鑰簾範簾範鑰) 更多	-	2024-10-08
				Placebo Oral Tablet (Placebo Tablets)	壓壓觸窪獵簾壓淵範衊(願窪餘積齋鹽構鹽糧蓋) = 餘選鹹夢蓋選網網獵淵構選壓夢築繭醖壓繭製 (積膚網蓋範鹹願遞築簾, 窪網艱憲齋選顧範製網 ~ 鹽糧憲鏇夢窪醖簾衊廠) 更多